1 Mesothelioma: What s New? Introduction Second revision of the scientific literature on malignant pleural mesothelioma (MPM). What new discoveries, studies and research protocols have been developed during the last few months? How is research progressing on mesothelioma, a subject close to our hearts? PubMed, the free access database containing articles, references, abstracts, revisions, etc., about science and medicine, serves as the definitive starting point for this new revision. We therefore consulted all the scientific literature published between January 1 and June 30, Under the general topic of Mesothelioma, we found the following for this period: total publications - By filtering the search to studies conducted in humans only, we narrowed it down to 75 studies during the last 6 months (not bad for a disease considered rare by some!) Our revision does not claim to be a scientific review, but it offers patients, their families and general practitioners a concise idea of the latest scientific research on mesothelioma. This is not a critical analysis of individual articles, rather it is a recent snapshot of the most well-known scientific bibliography in the world. People who would like more detailed information can delve further into the topics by reviewing the references provided at the end of this short revision. Diagnosis Various research groups are looking for new biomarkers that can be used to diagnose MPM. For example, claudin-4 is a protein involved in cellular junctions and is considered a useful immunohistochemical biomarker to distinguish between epithelioid mesothelioma and carcinoma metastases i.
2 Another biomarker being studied is BAP1, which is a deubiquitylase involved in the cellular cycle, gluconeogenesis, response to DNA damage, cellular differentiation and cell death. Researchers have discovered that a germline mutation of BAP1 may be associated with a syndrome that causes melanoma in young people and may lead to the development of mesothelioma, uveal and cutaneous melanoma, and perhaps other neoplasms in older people ii. Other noteworthy mesothelioma iii biomarkers currently under investigation include fibulin iv v vi, PTEN vii, GLUT, MCT-1 and MCT-4 viii, IMP3 ix. New technologies and methods are currently being defined for earlier and better identification of this disease x, others could be developed in addition to those already existing to provide further information xi. Mesothelioma must be differentiated from other benign diseases such as fibrous pleuritis. Several researchers are focusing on this topic and have evaluated a biomarker that could distinguish between these two diseases xii. The distinction between mesothelioma and lung cancer is also important, especially because it leads to different treatment approaches; this topic is also being studied xiii. In addition to biomarkers, we must not forget the importance of differential diagnosis xiv and an accurate case history to determine the possibility of environmental exposure xv xvi xvii xviii xix so we can arrive at the most accurate and early diagnosis possible. Therapy Notwithstanding the increased survival rate obtained through multimodal therapy based on a combination of surgery and chemotherapy, we need new treatments to further improve the results. With this in mind, new therapeutic approaches are appearing on the horizon for the treatment of MPM. Several researchers have investigated the administration chemotherapy or other agents directly into the thoracic or pleural cavity xx xxi xxii. Effective results have not yet been obtained, however. There have been a few case reports of spontaneous remission after intratumoral lymphocytic infiltration, which have increased the median survival rate. Based on these reports, several researchers are investigating the results further. For example, studies on immunotherapeutic approaches for MPM are underway with the aim of obtaining better results than those offered by standard therapy xxiii. Various studies have shown that patients who develop post-operative empyema after pulmonary resection have an improved survival rate.
3 Based on this data, we can hypothesize about the importance of the immune system against the tumor and the need to find drugs that can increase the immune response against cancer xxiv xxv xxvi. Various studies have investigated the intrapleural injection of Calmette-Guerin bacillus as an adjuvant to surgery, but significant clinical benefits have not yet been obtained xxvii. Various studies have investigated the systemic administration of immunotherapy such as interleukin and interferon gamma. However, the results thus far have been no more effective than current therapy and it is important to evaluate the side effects to determine the risk versus the benefit of these treatments xxviii xxix. Several researchers have analyzed the possibility of administering immunostimulant cytokines into the intrapleural cavity to treat MPM. Their research has shown a significant tumoral response using both IL2 and IFN gamma. The treatment seems more effective in patients with early stage MPM and these results could be truly promising xxx xxxi xxxii xxxiii xxxiv. The search for an adequate, effective treatment for MPM continues and new methods for novel, more effective and less toxic approaches are under investigation. Gene therapy and new, emerging technologies in particular are examining the use of transfer genes to potentially transport cancer drugs. Gene vectors have been researched in clinical and preclinical studies and are characterized by complex liposomes/dna or modified viruses, including herpes, vaccinia and adenoviruses xxxv xxxvi. The results from these studies have been mixed and need further research, but they are promising and offer much hope for the future. Several researchers xxxvii have documented a dose-dependent response to intrapleural administration. The case of two long surviving patients whose disease stabilized after 6 months was reported a few years later xxxviii. Also reported xxxix were complete responses to the treatment, partial responses and stable disease evaluations after therapy xl xli xlii xliii. There has been much discussion about suicide gene therapy and cytokine gene therapy. Suicide gene therapy is a treatment characterized by the transduction of tumor cells with a gene codifying for an enzyme that induces sensitivity to the chemotherapy drugs normally used. In other words, a prodrug is transformed into a toxic metabolite by introducing an enzyme into the malignant cells, resulting in the death or suicide of the tumor cells xliv xlv xlvi xlvii xlviii xlix l. The rationale behind cytokine gene therapy is the fact that activated tumor cells cause the release of many immunostimulatory cytokines, which in turn leads to an immune response against cancer li lii liii liv.
4 Local administration of these cytokines could certainly avoid the side effects that have been documented with systemic administration lv lvi lvii lviii lix. All these new treatments have led to improved patient survival and quality of life than in the past. New studies will certainly help offer patients new hope for the future. Conclusions This is the latest news on the scientific research being conducted to find new treatments for MPM. We must emphasize that these clinical studies need further investigation and more data before they can be translated into clinical practice. Nonetheless, guidelines for the diagnosis and treatment of this disease are being used on a daily basis. Continual congresses and conferences allow physicians to remain up-to-date and exchange information about new scientific achievements. For example, recommendations on total MPM patient care were published following the Second Italian consensus conference on malignant pleural mesothelioma lx. We therefore propose that MPM patients consult clinical centers dedicated to this disease in order to receive care that is personalized and focused on the patient rather than just the disease, in the knowledge that there is an answer to the question posed at the beginning of this article: are scholars, scientists and researchers making progress in their work? Are they focusing on a subject that is close to our hearts? Are they studying mesothelioma? The answer is yes.
5 References i Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Ordóñez NG. Am J Clin Pathol May;139(5): doi: /AJCP0B3YJBXWXJII. ii BAP1 and cancer. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. Nat Rev Cancer Mar;13(3): iii Eur Respir J Jan;41(1): doi: / Epub 2012 Jul 12. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA. iv Select item Fibulin-3 as a biomarker for pleural mesothelioma. Hollevoet K, Sharon E. N Engl J Med Jan 10;368(2):189. doi: /NEJMc #SA1. No abstract available. v Fibulin-3 as a biomarker for pleural mesothelioma. Lamote K, Baas P, van Meerbeeck JP. N Engl J Med Jan 10;368(2): doi: /NEJMc #SA2. No abstract available. vi Fibulin-3 as a biomarker for pleural mesothelioma. Pass HI, Goparaju C.N Engl J Med Jan 10;368(2):190. doi: /NEJMc No abstract available. vii Tumour Biol Apr;34(2): doi: /s Epub 2012 Dec 15. PTEN protein expression in malignant pleural mesothelioma. Agarwal V, Campbell A, Beaumont KL, Cawkwell L, Lind MJ. viii Virchows Arch Jan;462(1): doi: /s Epub 2012 Nov 28. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K. ix IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
6 Lee AF, Gown AM, Churg A. Am J Surg Pathol Mar;37(3): doi: /PAS.0b013e31826ab1c0. x Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods. Jing X, Li QK, Bedrossian U, Michael CW. Am J Clin Pathol Feb;139(2): doi: /AJCP83ADULCXMAIX. xi Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S. Cancer Invest Jan;31(1): doi: / Epub 2012 Dec 18. xii Diagnostic usefulness of p16/cdkn2a FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, Fujino M, Yamakawa H, Nakatani Y, Tada Y, Shimada H, Tagawa M. Am J Clin Pathol Jan;139(1): doi: /AJCPT94JVWIHBKRD. xiii J Clin Pathol Mar;66(3): doi: /jclinpath Epub 2012 Oct 19. xiv Extrapulmonary small cell carcinoma mimicking malignant pleural mesothelioma. Noguchi K, Fujimoto N, Asano M, Fuchimoto Y, Ono K, Ozaki S, Hotta K, Kato K, Toda H, Taguchi K, Kishimoto T. J Clin Pathol May;66(5): doi: /jclinpath Epub 2013 Feb 15. No abstract available. xv Int J Cancer Mar 15;132(6): doi: /ijc Epub 2012 Aug 16. Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia. de Klerk N, Alfonso H, Olsen N, Reid A, Sleith J, Palmer L, Berry G, Musk AB. xvi Autopsy findings and pleural plaques in the Malignant Mesothelioma (MM) Regional Register of Friuli-Venezia-Giulia. De Zotti R, Barbati G, Negro C. Med Lav Jan-Feb;104(1): Italian. xvii Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Gibb H, Fulcher K, Nagarajan S, McCord S, Fallahian NA, Hoffman HJ, Haver C, Tolmachev S. Am J Public Health Apr;103(4): doi: /AJPH Epub 2013 Feb 14.
7 xviii Researchers explore possible link between mesothelioma and dust emissions in southern Nevada. O'Hanlon LH. J Natl Cancer Inst Mar 6;105(5): doi: /jnci/djt033. Epub 2013 Feb 12. No abstract available. xix High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites. Bayram M, Dongel I, Bakan ND, Yalçin H, Cevit R, Dumortier P, Nemery B. Chest Jan;143(1): Erratum in: Chest Mar;143(3):880. xx Monneuse O, Beaujard AC, Guibert B, et al. Longterm results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. BrJ Cancer 2003;88:1839. xxi IkeO,ShimuzuV,Hitomi S,et al. Treatment ofmalignant pleural effusions with doxorubicin hydrochloridecontaining ply (L-lactic acid) microspheres. Chest 1991;99:911. xxii van Ruth S, Baas P, Haas RL, et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003;10: 176. xxiii Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103:373S. xxiv Lawaetz O, Halkier E. The relationship between postoperative empyema and long-term survival after pneumonectomy. Results of surgical treatment of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1980;14(1): xxv Minasian H, Lewis CT, Evans SJ. Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma. Br Med J 1978;2(6148): xxvi Bone G. Postoperative empyema and survival in lung cancer. Br Med J 1973;2(5859):178. xxvii Bakker W, Nijhuis-Heddes JM, van der Velde EA. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 1986;22(2):155 9.
8 xxviii Robinson BW, Manning LS, Bowman RV, et al. The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 1993;3:195. xxix Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998;83:2099 xxx Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998;21(5): xxxi Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant mesothelioma. Cancer 1994; 74:2460. xxxii Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991;67:2033. xxxiii Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I- II study. Br J Cancer 1995;72:1283. xxxiv Nowak AK, Lake RA, Kindler HL, et al. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002;29:82. xxxv Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998;21:211 xxxvi Vachani A, Moon E, Wakeam E, et al. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010;42(4): xxxvii Sterman D, Treat J, Litzky LA, et al. Adenovirusmediated herpes simplex virus thymidine kinase/ ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083.
9 xxxviii Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511. xxxix Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: xl Sterman DH, Recio A, Haas AR, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon- beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18(4): xli Sterman DH, Haas AR, Moon E, et al. A trial of intrapleural adenoviral-mediated interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184: xlii Dong M, Li X, Hong LJ, et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 2008;36: xliii Schwarzenberger P, Byrne P, Gaumer R, et al. Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 2011;18(12): xliv Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7. xlv Smythe WR, Hwang HC, Amin KM, et al. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplexthymidine kinase gene. Ann Surg 1995;222:78. xlvi Sterman D, Treat J, Litzky LA, et al. Adenovirusmediated herpes simplex virus thymidine kinase/ ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083.
10 xlvii Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511. xlviii Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005;11(20): xlix Schwarzenberger P, Lei DH, Freeman SM, et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998;19:333. l Schwarzenberger P, Byrne P, Gaumer R, et al. Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 2011;18(12): li Sterman DH, Recio A, Haas AR, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon- beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18(4): lii Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: liii Sterman DH, Haas AR, Moon E, et al. A trial of intrapleural adenoviral-mediated interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184: liv Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediated regression of human disseminated tumor. Cancer Res 2010; 70(22): lv Vachani A, Moon E, Wakeam E, et al. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010;42(4):
11 lvi Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998;21:211. lvii Mukherjee S, Haenel T, Himbeck R, et al. Replication- restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000;7:663. lviii Odaka M, Sterman D, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirusmediated interferon-beta gene therapy due to induction of systemic immunity. Cancer Res 2001; 61: lix Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007;2(4): lx Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G. Cancer Treat Rev Jun;39(4): doi: /j.ctrv Epub 2012 Dec 12. Review.
Group 63 Seminar on Magnetism Massachusetts Institute of Technology Digital Computer Laboratory Archives Collection No. 12 Donor: Division VI Document Room Restriction: MITRE Personnel Contract a19( 122)
GUIDELINES FOR ONLINE SUBMISSION OF APPLICATIONS Important Note/Information for the applicants: It is in the interest of the applicants to study in detail and thoroughly observe the guidelines given in
Internet, broadband, and cell phone statistics By: Lee Rainie, Director January 5, 2010 Overview In a national survey between November 30 and December 27, 2009, we find: 74% of American adults (ages 18
SHIPS FROM MADRAS NAME OF SHIP DATE OF ARRIVAL Truro November 16, 1860 Lord George Bentinck December 24, 1860 Tyburnia March 20, 1861 Earl of Hardwick September 21, 1863 Scindian October 29, 1863 Rajasthana
4820 8 TH STREET SALEM, OREGON 97301 C&A MM Inventory Relieve & Post to Job Cost Installation and Setup Instructions with Process Flow The general purpose of this program is to relieve parts from inventory
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
Table of contents Key facts and statistics about volunteering in Australia Introduction.. page 2 How many people volunteer.page 2 Formal Informal Who volunteers..page 3 Gender Disability Cultural and linguistic
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
Business Administration of Windchill PDMLink 10.0 Overview Course Code Course Length TRN-3160-T 3 Days After completing this course, you will be well prepared to set up and manage a basic Windchill PDMLink
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
Monterey County Behavioral Health Policy and Procedure Policy Title Alcohol and Other Drug Programs - Narcotic Treatment Programs References See each specific subsection for applicable references Effective
INFORMATION SHEET FOR LEGAL PRACTIONERS KEY DIFFERENCES BETWEEN THE UNIFORM LAW AND THE NEW SOUTH WALES AND VICTORIAN LEGAL PROFESSION ACTS The Legal Profession Uniform Law (Uniform Law) commenced in NSW
JUNE 6, 2012 Older adults and internet use For the first time, half of adults ages 65 and older are online Kathryn Zickuhr Research Specialist, Pew Internet Project Mary Madden Senior Research Specialist,
CHAPTER 1 GENERAL PROVISIONS Section 1. Authority. (a) These rules and regulations are promulgated by the Wyoming State Board of Nursing pursuant to it s authority under the Wyoming Nurse Practice Act,
What s New in Microsoft Office Project 2003 Getting Help Getting Help with This Book and Its CD-ROM Getting Help with Microsoft Office Project 2003 Using the Book s CD-ROM What s on the CD-ROM System Requirements
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
Professional Indemnity Proposal Form Specific and Miscellaneous Professions Please complete the whole form to the best of your ability, clarifying any areas where necessary and continuing on a separate
R162-2f-206c. Certification of Continuing Education Course. (1) (a) The division may not award continuing education credit for a course that is advertised in Utah to real estate licensees unless the course
Prologis European Properties Per Unit U.S. Taxable Income Allocation* For the Period from January 1, 2012 through August 27, 2012 Common Unit Allocation Total 1/1/12-8/27/12 Per Unit Allocation Per Unit
NATO STANDARD AMedP-8.1 DOCUMENTATION RELATIVE TO INITIAL MEDICAL TREATMENT AND EVACUATION Edition A Version 1 JUNE 2013 NORTH ATLANTIC TREATY ORGANIZATION ALLIED MEDICAL PUBLICATION Published by the NATO
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
Who is following me? Tracking the trackers A background paper for a workshop co-organised by the Council of Europe and the Internet Society at the Internet Governance Forum in Baku, Azerbaijan in November
MESOMARK, Brochure Interest in any of the products, request or order them at Bio-Connect Diagnostics. Bio-Connect Diagnostics B.V. T NL +31 () 3 T BE +3 () 5 1 53 Begonialaan 3a F NL +31 () 3 1 F BE +3
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
Pew Internet & American Life Project Project for Excellence in Journalism Knight Foundation DECEMBER 14, 2011 A Closer Look Where people get information about restaurants and other local businesses The
Genetic Therapy for Malignant Pleural Mesothelioma: 1993-2013 Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Chief, Section of Interventional Pulmonology and Thoracic Oncology Pulmonary,
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
by Christian Classics Ethereal Library About Book of Needs of the Holy Orthodox Church by Title: URL: Author(s): Publisher: Print Basis: Rights: Date Created: Status: CCEL Subjects: Book of Needs of the
Curriculum Map Outline Implementation 9.1.13 Revision Date 1.6.14 Algebra I Unit Guidelines for Curriculum UNIT 1: 27 DAYS Unit 1 - Single Variable Expressions/Equations/Inequalities I. Unit Summary/Essential
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility
Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey
CURRICULUM VITAE ALEXANDER ALEC R. ROTHROCK Born Evanston, Illinois 1959 Burns, Figa & Will, P.C. Plaza Tower One, Suite 1000 6400 South Fiddler s Green Circle Greenwood Village, CO 80111 Telephone: (303)
For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
The New York City Department of Education (NYC DOE), part of city government, operates the largest school district in the country with about 1,600 schools and 1.1 million students. There are 400 high schools
BSM 9.0 ESSENTIALS Instructor-Led Training INTENDED AUDIENCE New users of Business Service Management (BSM) 9.0, including: Database Administrators System Administrators Network Administrators Operations
NATIONAL BANK OF GREECE S.A. ARTICLES OF ASSOCIATION BoD SECRETARIAT & SHAREHOLDER SERVICES DIVISION SHAREHOLDER SERVICES SUB-DIVISION MAY 2014 NATIONAL BANK OF GREECE S.A. PREAMBLE These articles of association
Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz
Introduction to Windchill PDMLink 10.0 for Heavy Users Overview Course Code Course Length TRN-3146-T 2 Days In this course, you will learn how to complete the day-to-day functions that enable you to create
Research Note Patient Lives In Our [Robotic] Hands: Risks and Implications of Robotic Surgery By: Brooke R. Brisbois Copyright 2014, ASA Institute for Risk & Innovation Applicable Sectors: Healthcare Keywords:
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 email@example.com
Workflow Administration of Windchill 10.2 Overview Course Code Course Length TRN-4339-T 2 Days In this course, you will learn about Windchill workflow features and how to design, configure, and test workflow
Alternative Teacher Certification Emily De Yoe Education Law and Policy May 14, 2009 I. Introduction Six out of every 100 freshmen entering a Chicago Public School (CPS) will have a college degree by their
Michigan Geological Survey Report 10 from the K-12 Outreach Director, Peter Voice [May 23, 2014] New Items: 1. May 9: Contacted by Katie Bir, Sturgis District Library I sent her copies of our brochures
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
A good childhood for every child? Child Poverty in the UK Introduction The Children's Society believes that child poverty is an intolerable injustice that blights childhoods and severely harms children's
Monterey County Behavioral Health Policy and Procedure Policy Title Alcohol and Other Drug (AOD) Programs Residential Alcoholism or Drug Abuse Recovery or Treatment Facilities References See each specific
The Count of Monte Cristo Chapter I 1. How does Dumas establish the theme of good versus evil, as well as set the story in motion? 2. What roles do history and politics play in the opening of the story?
PROCUREMENT AND CONTRACT GUIDELINES OF THE HOUSING TRUST FUND CORPORATION FOR CONTRACTS EXCLUDING THOSE FUNDED BY THE U.S. DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT S COMMUNITY DEVELOPMENT BLOCK GRANT
LIFE INSURANCE PRODUCTS, PERFORMANCE EVALUATION AND CUSTOMER SATISFACTION IN THE REGIME OF IRDA A COMPARATIVE STUDY OF LIC OF INDIA & ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED Insurance is an umbrella
Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event
Malignant Mesothelioma Recent Advances Dr AS Paul 04 Aug 06 DM Seminar Malignant mesothelioma A tumour of serosal surfaces Pleura, peritoneum Increasing incidence worldwide Association with asbestos exposure
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
ERISA FIDUCIARY RESPONSIBILITY: FIDUCIARY RELIANCE ON REGISTERED INVESTMENT ADVISORS WHITE PAPER Gary J. Caine, FSA REGIONAL DIRECTOR INTRODUCTION Plan sponsors have become more concerned about the investments
MARCH 9, 2012 Search Engine Use 2012 Even though online Americans are more satisfied than ever with the performance of search engines, strong majorities have negative views of personalized search results
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis . Most are
Reading Habits Survey Final Revised Topline 01/04/2012 Data for November 16 December 21, 2011 for the Pew Research Center s Internet & American Life Project Sample: n=2,986 people age 16+, including an
CRIMINAL TRIAL REFORM CONFERENCE Paper 4 The Duty of Disclosure on the Prosecution Ms Wendy Abraham QC* A prosecutor must play his or her part in securing a fair trial for persons accused of criminal offences.
EXPORT PROMOTION COUNCIL FOR EOUs & SEZ UNITS (Ministry of Commerce & Industry, Government of India) 705, BHIKAJI CAMA BHAVAN, BHIKAJI CAMA PLACE, NEW DELHI 110 066 TEL : 26165805, 26167042, FAX: 26165538,
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
CANNOCK CHASE COUNCIL MINUTES OF THE MEETING OF THE GRANT APPLICATIONS AND RATE RELIEF COMMITTEE TUESDAY, 7 MARCH 2006 AT 2.00 P.M. HELD IN THE CIVIC CENTRE, BEECROFT ROAD, CANNOCK PART 1 PRESENT: Councillors
Case Study PRINCE2 and PMI/PMBOK A Combined Approach at Getronics The APM Group Limited 7-8 Queen Square High Wycombe Buckinghamshire HP11 2BP Tel: + 44 (0) 1494 452450 Fax + 44 (0) 1494 459559 www.apmgroup.co.uk
BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC firstname.lastname@example.org Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
Pre-service Performance Assessment (PPA) Guidelines for Teachers July 2013 Massachusetts Department of Elementary and Secondary Education 75 Pleasant Street, Malden, MA 02148-4906 Phone 781-338-3000 TTY:
Asbestos Health Risks Dr Andrew Pengilley Acting Chief Health Officer Asbestos Asbestos is a name given to several different fibrous minerals Three main commercial types are Chrysotile (white asbestos)
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression